Key facts
- Lindus’s last known valuation is $286.4M (Jan 2025).
- It has raised $81.3M; the latest was Early Stage VC ($55.2M) in Jan 2025.
- Notable investors include Innovate UK, Tech Nation Group, Seedcamp, Salica Investments, Balderton Capital — 29 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 29 names
- ·Watchlist + deal alerts for Lindus
- ·The full record, as it builds
Funding rounds
No funding rounds for Lindus are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lindus
Developer of a clinical research platform designed to manage and execute clinical trials with improved speed and oversight. The company offers integrated trial operations, centralized enrollment infrastructure, flexible site models, and an AI-native operating system, enabling biotechnology and pharmaceutical organizations to conduct studies efficiently and meet timelines.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2021
- Employees
- 99
- Website
- lindushealth.com/
- Ownership
- Privately Held (backing)
Lindus doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lindus shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lindus in its N-PORT filings yet. We sweep new filings monthly.